Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 15.23% is 88% above its 5-year average of 8.10%, near the high end of its 5-year range (0.00%–19.56%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.66% above its 12-month average of 14.02%.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2026 (2026-06-30): 15.23%.
DEBT TO ASSETS RATIO
15.23%
DEBT TO ASSETS RATIO AVG TTM
14.02%
DEBT TO ASSETS RATIO AVG 3Y
11.26%
DEBT TO ASSETS RATIO AVG 5Y
8.10%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+8.66%
CURRENT VS 3Y AVG
+35.27%
CURRENT VS 5Y AVG
+88.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 866 covered companies
CURRENT VS SECTOR MEDIAN
+16826.11%
vs the sector median at left
Intelligent Bio Solutions Inc.
Market Cap
$5.21M
Debt to Assets Ratio
15.23%
TTM Avg
14.02%
3Y Avg
11.26%
5Y Avg
8.10%
Market Cap
$5.23M
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.03M
Debt to Assets Ratio
0.49%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.00M
Debt to Assets Ratio
0.42%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intelligent Bio Solutions Inc. (INBS) | $5.21M | 15.23% | 14.02% | 11.26% | 8.10% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | 0.25% | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.26M | 0.00% | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | 0.14% | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | 0.00% | N/A | N/A | N/A |
| Soligenix, Inc. (SNGX)vs › | $5.34M | 0.03% | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | 0.52% | N/A | N/A | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | 0.49% | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | 0.42% | N/A | N/A | N/A |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.94M | 0.00% | N/A | N/A | N/A |
Debt/Assets
15.2%
Debt/Equity
0.33
Current Ratio
1.44
Interest Coverage
-1174.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 15.23% |
| 2026-03-31 | 12.44% |
| 2025-12-31 | 19.56% |
| 2025-09-30 | 19.44% |
| 2025-06-30 | 3.42% |
| 2025-03-31 | 5.33% |
| 2024-12-31 | 7.21% |
| 2024-09-30 | 6.32% |
| 2024-06-30 | 8.32% |
| 2024-03-31 | 5.48% |
| 2023-12-31 | 12.25% |
| 2023-09-30 | 12.90% |
| 2023-06-30 | 18.50% |
| 2023-03-31 | 10.39% |
| 2022-12-31 | 13.26% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 176.65% |
| 2020-06-30 | 207.37% |
| 2020-03-31 | 265.20% |
| 2019-09-30 | 169.67% |
| 2019-06-30 | 220.42% |
| 2019-03-31 | 244.16% |
| 2018-06-30 | 193.91% |
